-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Introducing Car-T-MHC/KO
Author:
InnoModels Biotechnology
Release time:
2024-01-15
In the wave of innovation in the biomedical field, InnoModels Biotechnology has attracted widespread attention with its unique technology, Car-T-MHC/KO (Car-T cell-MHC knockout). The application of this technology gives new life to CAR-T cell therapy and brings brand new possibilities to the field of cancer treatment.
Background
1. CAR-T cell therapy:
CAR-T cell therapy is a revolutionary therapy that works by modifying a patient's own T cells so that they can actively attack cancer cells. However, conventional CAR-T cell therapy still faces several challenges, including immune rejection and antigen loss.
2. Car-T-MHC/KO technology:
InnoModels's Car-T-MHC/KO technology effectively circumvents the risk of immune rejection by knocking out the MHC (major histocompatibility complex) in CAR-T cells. This innovative technology makes CAR-T cells more invisible and improves their survival time in patients.

Technical Features
1. Advantage of MHC knockdown:
MHC is a key component for T cells to recognize foreign substances, but it is also an easy target for immune rejection. car-T-MHC/KO technology avoids this problem by precisely knocking out MHC, making CAR-T cells more controllable and safe in patients.
2. Enhanced efficacy:
Car-T-MHC/KO technology not only solves the problem of immune rejection, but also improves the anti-tumor activity of CAR-T cells to a certain extent. This makes the therapeutic effect more significant and brings better chances of survival for patients.
Clinical Application and Prospect
1. Clinical trial results:
InnoModels Biotechnology has achieved a series of exciting results in the clinical trials of Car-T-MHC/KO technology. Preliminary data show that the technology is not only safe and controllable, but also demonstrates excellent efficacy in a wide range of cancer types.
2. Therapeutic area expansion:
The successful application of Car-T-MHC/KO technology opens up unlimited possibilities for therapeutic expansion. In the future, with the in-depth study of this technology in more cancer types and diseases, it is expected to become a disruptive force in cancer treatment.
Conclusion
InnoModels's Car-T-MHC/KO technology has made impressive breakthroughs in the field of CAR-T cell therapy, bringing a new dawn for cancer patients. This innovative treatment not only technically solves the problems of traditional CAR-T cell therapy, but also provides a safer and more effective treatment option for patients. Looking ahead, Car-T-MHC/KO technology is expected to become a shining star in the field of cancer treatment, bringing more hope to patients.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd